JP2023018073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023018073A5 JP2023018073A5 JP2022186724A JP2022186724A JP2023018073A5 JP 2023018073 A5 JP2023018073 A5 JP 2023018073A5 JP 2022186724 A JP2022186724 A JP 2022186724A JP 2022186724 A JP2022186724 A JP 2022186724A JP 2023018073 A5 JP2023018073 A5 JP 2023018073A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- recombinant protein
- helix
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 36
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 36
- 101710154606 Hemagglutinin Proteins 0.000 claims description 28
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 28
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 28
- 101710176177 Protein A56 Proteins 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 206010022000 influenza Diseases 0.000 claims description 15
- 239000002105 nanoparticle Substances 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 239000000185 hemagglutinin Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 7
- 229940024606 amino acid Drugs 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 235000004554 glutamine Nutrition 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 108010068996 6,7-dimethyl-8-ribityllumazine synthase Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091170A JP2024123036A (ja) | 2016-09-02 | 2024-06-05 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383267P | 2016-09-02 | 2016-09-02 | |
| US62/383,267 | 2016-09-02 | ||
| PCT/US2017/049894 WO2018045308A1 (en) | 2016-09-02 | 2017-09-01 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
| JP2019512267A JP7183149B2 (ja) | 2016-09-02 | 2017-09-01 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512267A Division JP7183149B2 (ja) | 2016-09-02 | 2017-09-01 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091170A Division JP2024123036A (ja) | 2016-09-02 | 2024-06-05 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023018073A JP2023018073A (ja) | 2023-02-07 |
| JP2023018073A5 true JP2023018073A5 (enExample) | 2023-03-20 |
| JP7500692B2 JP7500692B2 (ja) | 2024-06-17 |
Family
ID=59887401
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512267A Active JP7183149B2 (ja) | 2016-09-02 | 2017-09-01 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
| JP2022186724A Active JP7500692B2 (ja) | 2016-09-02 | 2022-11-22 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
| JP2024091170A Pending JP2024123036A (ja) | 2016-09-02 | 2024-06-05 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512267A Active JP7183149B2 (ja) | 2016-09-02 | 2017-09-01 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091170A Pending JP2024123036A (ja) | 2016-09-02 | 2024-06-05 | 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11338033B2 (enExample) |
| EP (1) | EP3506938A1 (enExample) |
| JP (3) | JP7183149B2 (enExample) |
| KR (2) | KR20190056382A (enExample) |
| CN (2) | CN110167585B (enExample) |
| AU (2) | AU2017321883B2 (enExample) |
| BR (1) | BR112019004189A2 (enExample) |
| CA (1) | CA3035443A1 (enExample) |
| IL (3) | IL265121B2 (enExample) |
| SG (2) | SG11201901790YA (enExample) |
| WO (1) | WO2018045308A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105792842B (zh) | 2013-10-11 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 埃巴病毒疫苗 |
| IL265121B2 (en) * | 2016-09-02 | 2023-11-01 | Us Health | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
| GB2578163A (en) * | 2018-10-19 | 2020-04-22 | Univ Pretoria | Plant produced avian influenza antigens and their uses in diagnostic assays and devices |
| CN113423718A (zh) | 2019-02-08 | 2021-09-21 | 美国政府(由卫生和人类服务部的部长所代表) | 基于纳米颗粒的流感病毒疫苗及其用途 |
| WO2021174132A2 (en) * | 2020-02-26 | 2021-09-02 | The Wistar Institute Of Anatomy & Biology | Compositions comprising self-assembling vaccines and methods of using the same |
| CN111560074B (zh) * | 2020-03-20 | 2021-07-09 | 中山大学 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗 |
| WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
| WO2022200582A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| CA3212653A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| EP4362974A1 (en) | 2021-06-28 | 2024-05-08 | GlaxoSmithKline Biologicals S.A. | Novel influenza antigens |
| US20240374709A1 (en) | 2021-09-16 | 2024-11-14 | Emergent Product Development Gaithersburg Inc. | Vaccine compositions |
| WO2023061993A1 (en) | 2021-10-13 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Polypeptides |
| GB202219228D0 (en) | 2022-12-20 | 2023-02-01 | Glaxosmithkline Biologicals Sa | Novel influenza antigens |
| WO2024131862A1 (zh) * | 2022-12-22 | 2024-06-27 | 北京吉诺卫生物科技有限公司 | 一种rsv疫苗及其制备方法与应用 |
| CN115850396B (zh) * | 2022-12-22 | 2024-02-06 | 北京吉诺卫生物科技有限公司 | 一种rsv纳米颗粒疫苗及其制备方法与应用 |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| WO2024167855A1 (en) | 2023-02-06 | 2024-08-15 | Emergent Product Development Gaithersburg Inc. | Influenza hemagglutinin constructs and compositions |
| WO2024197134A1 (en) * | 2023-03-21 | 2024-09-26 | President And Fellows Of Harvard College | Coronavirus spike protein-based vaccines |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
| CA2776522C (en) | 2001-10-01 | 2015-02-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| US20050108791A1 (en) | 2001-12-04 | 2005-05-19 | Edgerton Michael D. | Transgenic plants with improved phenotypes |
| CN1659187A (zh) | 2002-05-10 | 2005-08-24 | 新世纪药品有限公司 | 融合铁蛋白在疫苗和其他方面的应用 |
| RU2324704C2 (ru) * | 2002-07-17 | 2008-05-20 | Цитос Байотекнолоджи Аг | Молекулярные массивы антигенов |
| WO2004020454A2 (en) | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
| CA2816222A1 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| GB0319797D0 (en) | 2003-08-26 | 2003-09-24 | Leuven K U Res & Dev | Particle size reduction of poorly soluble drugs |
| WO2007032241A1 (ja) | 2005-09-12 | 2007-03-22 | Japan Science And Technology Agency | 微粒子-タンパク質複合体およびその作製方法、半導体装置、蛍光標識方法 |
| EP2476432B1 (en) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| CA2673994A1 (en) | 2006-12-29 | 2008-07-24 | Institut Pasteur Of Shanghai | Lentivirus pseudotyped with influenza hemagglutinin and methods of use |
| WO2008145129A2 (en) | 2007-05-31 | 2008-12-04 | Statens Serum Institut | Influenza vaccines |
| US8778847B2 (en) | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| CA2696764A1 (en) | 2007-08-20 | 2009-02-26 | Fraunhofer Usa, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
| RU2540871C2 (ru) | 2008-02-01 | 2015-02-10 | Альфа-О Пептидес Аг | Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин |
| JP5382489B2 (ja) | 2008-03-29 | 2014-01-08 | 国立大学法人 奈良先端科学技術大学院大学 | 円偏光発光性ナノ微粒子 |
| US20110177122A1 (en) | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
| EP2413962A1 (en) | 2009-03-30 | 2012-02-08 | Mount Sinai School of Medicine | Influenza virus vaccines and uses thereof |
| HRP20171564T1 (hr) | 2009-09-22 | 2017-11-17 | Medicago Inc. | Postupak za pripremu biljnih čestica sličnih virusu (vlp) |
| US20120219584A1 (en) | 2009-10-05 | 2012-08-30 | The United States Of America As Represented By The Secretary, Department Of Health | Protection against pandemic and seasonal strains of influenza |
| US9352031B2 (en) | 2010-02-18 | 2016-05-31 | Technovax, Inc. | Universal virus-like particle (VLP) influenza vaccines |
| US9512182B2 (en) * | 2010-12-13 | 2016-12-06 | University Of Utah Research Foundation | Vaccine antigens that direct immunity to conserved epitopes |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| IN2014CN02114A (enExample) | 2011-09-20 | 2015-05-29 | Sinai School Medicine | |
| CA2849822C (en) * | 2011-09-23 | 2021-05-11 | Gary J. Nabel, M.D. | Novel influenza hemagglutinin protein-based vaccines |
| MY170927A (en) * | 2011-11-28 | 2019-09-19 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| JP2015519348A (ja) * | 2012-05-23 | 2015-07-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | インフルエンザワクチン構築物 |
| EP4154907A1 (en) * | 2012-12-18 | 2023-03-29 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| EA034639B1 (ru) * | 2013-05-30 | 2020-03-02 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцины против вируса гриппа и их применения |
| CN105792842B (zh) | 2013-10-11 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 埃巴病毒疫苗 |
| EP3063273B8 (en) | 2013-10-28 | 2020-12-30 | Blue Sky Vaccines GmbH | Influenza virus vector for virotherapy |
| CN114014937A (zh) * | 2014-05-27 | 2022-02-08 | 美利坚合众国, 由健康及人类服务部部长代表 | 稳定化的流感血凝素茎区三聚体及其用途 |
| MY182440A (en) | 2014-07-10 | 2021-01-25 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| JP6824154B2 (ja) | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | 修飾エンベロープタンパク質e3を含むウイルス様粒子 |
| SG11201705264WA (en) | 2014-12-31 | 2017-07-28 | The Usa As Represented By The Secretary Detp Of Health And Human Services | Novel multivalent nanoparticle-based vaccines |
| US10961283B2 (en) * | 2016-06-27 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| IL265121B2 (en) * | 2016-09-02 | 2023-11-01 | Us Health | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
| WO2021231729A1 (en) * | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
-
2017
- 2017-09-01 IL IL265121A patent/IL265121B2/en unknown
- 2017-09-01 SG SG11201901790YA patent/SG11201901790YA/en unknown
- 2017-09-01 CA CA3035443A patent/CA3035443A1/en active Pending
- 2017-09-01 CN CN201780066267.2A patent/CN110167585B/zh active Active
- 2017-09-01 US US16/329,592 patent/US11338033B2/en active Active
- 2017-09-01 JP JP2019512267A patent/JP7183149B2/ja active Active
- 2017-09-01 EP EP17768316.6A patent/EP3506938A1/en active Pending
- 2017-09-01 KR KR1020197009334A patent/KR20190056382A/ko not_active Ceased
- 2017-09-01 WO PCT/US2017/049894 patent/WO2018045308A1/en not_active Ceased
- 2017-09-01 CN CN202410185751.9A patent/CN118146389A/zh active Pending
- 2017-09-01 IL IL303650A patent/IL303650B2/en unknown
- 2017-09-01 BR BR112019004189A patent/BR112019004189A2/pt unknown
- 2017-09-01 SG SG10201912944QA patent/SG10201912944QA/en unknown
- 2017-09-01 KR KR1020247010062A patent/KR20240042570A/ko active Pending
- 2017-09-01 AU AU2017321883A patent/AU2017321883B2/en active Active
- 2017-09-01 IL IL315821A patent/IL315821A/en unknown
-
2022
- 2022-05-11 US US17/742,201 patent/US11793871B2/en active Active
- 2022-10-07 AU AU2022246465A patent/AU2022246465B2/en active Active
- 2022-11-22 JP JP2022186724A patent/JP7500692B2/ja active Active
-
2023
- 2023-10-20 US US18/491,193 patent/US20240050554A1/en active Pending
-
2024
- 2024-06-05 JP JP2024091170A patent/JP2024123036A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023018073A5 (enExample) | ||
| JP2019537424A5 (enExample) | ||
| AU2022246465B2 (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
| Lamb et al. | Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface | |
| KR100715954B1 (ko) | 펩티드 리간드에 의하여 부착된 다중 면역원성 성분을보유한 hbv 코어 항원 입자 | |
| US20230340031A1 (en) | Self-assembling protein nanoparticles with built-in six-helix bundle proteins | |
| TWI874544B (zh) | 變異型rsv f蛋白質及其利用 | |
| JP7317047B2 (ja) | インフルエンザウイルスワクチン及びその使用 | |
| US20120009212A1 (en) | Conjugates utilizing platform technology for stimulating immune response | |
| CN105452270A (zh) | 流行性感冒病毒疫苗及其用途 | |
| JP2022530439A (ja) | 組換えインフルエンザ抗原 | |
| JP2011501950A5 (enExample) | ||
| US20160000901A1 (en) | Compositions and Methods for the Production of Virus-Like Particles | |
| AU2018388102A1 (en) | Cross-immunizing antigen vaccine and method for preparation thereof | |
| WO2018175560A1 (en) | Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain | |
| JP2024518548A (ja) | アミノ酸、ヌクレオチドおよびそれを発現するベクター、ならびにサルベコウイルス感染症の予防におけるそれらの使用 | |
| US12016920B2 (en) | Adjuvant based on peptide nucleic acid | |
| WO2025231007A1 (en) | Influenza vaccine compositions and methods of making and using same | |
| WO2025229334A1 (en) | Oligomeric hemagglutinin antigens | |
| WO2024199469A1 (zh) | 具有稳定融合前构象的呼吸道合胞病毒f蛋白 | |
| US20140154282A1 (en) | Conjugates utilizing platform technology for stimulating immune response | |
| HK1193339A (en) | Conjugates utilizing platform technology for stimulating immune response | |
| CN103242426A (zh) | 禽流感病毒h5n1亚型限制性ctl表位多肽及其应用 |